These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 24595352)

  • 1. Abrogating monoacylglycerol acyltransferase activity in liver improves glucose tolerance and hepatic insulin signaling in obese mice.
    Hall AM; Soufi N; Chambers KT; Chen Z; Schweitzer GG; McCommis KS; Erion DM; Graham MJ; Su X; Finck BN
    Diabetes; 2014 Jul; 63(7):2284-96. PubMed ID: 24595352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple antisense oligonucleotides targeted against monoacylglycerol acyltransferase 1 (Mogat1) improve glucose metabolism independently of Mogat1.
    Lutkewitte AJ; Singer JM; Shew TM; Martino MR; Hall AM; He M; Finck BN
    Mol Metab; 2021 Jul; 49():101204. PubMed ID: 33676028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibiting monoacylglycerol acyltransferase 1 ameliorates hepatic metabolic abnormalities but not inflammation and injury in mice.
    Soufi N; Hall AM; Chen Z; Yoshino J; Collier SL; Mathews JC; Brunt EM; Albert CJ; Graham MJ; Ford DA; Finck BN
    J Biol Chem; 2014 Oct; 289(43):30177-88. PubMed ID: 25213859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mogat1 deletion does not ameliorate hepatic steatosis in lipodystrophic (Agpat2-/-) or obese (ob/ob) mice.
    Agarwal AK; Tunison K; Dalal JS; Yen CL; Farese RV; Horton JD; Garg A
    J Lipid Res; 2016 Apr; 57(4):616-30. PubMed ID: 26880786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for regulated monoacylglycerol acyltransferase expression and activity in human liver.
    Hall AM; Kou K; Chen Z; Pietka TA; Kumar M; Korenblat KM; Lee K; Ahn K; Fabbrini E; Klein S; Goodwin B; Finck BN
    J Lipid Res; 2012 May; 53(5):990-999. PubMed ID: 22394502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoacylglycerol Acyltransferase 1 Knockdown Exacerbates Hepatic Ischemia/Reperfusion Injury in Mice With Hepatic Steatosis.
    Liss KHH; Ek SE; Lutkewitte AJ; Pietka TA; He M; Skaria P; Tycksen E; Ferguson D; Blanc V; Graham MJ; Hall AM; McGill MR; McCommis KS; Finck BN
    Liver Transpl; 2021 Jan; 27(1):116-133. PubMed ID: 32916011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice.
    Yu XX; Murray SF; Pandey SK; Booten SL; Bao D; Song XZ; Kelly S; Chen S; McKay R; Monia BP; Bhanot S
    Hepatology; 2005 Aug; 42(2):362-71. PubMed ID: 16001399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic monoacylglycerol acyltransferase 1 is induced by prolonged food deprivation to modulate the hepatic fasting response.
    Lutkewitte AJ; McCommis KS; Schweitzer GG; Chambers KT; Graham MJ; Wang L; Patti GJ; Hall AM; Finck BN
    J Lipid Res; 2019 Mar; 60(3):528-538. PubMed ID: 30610082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second-generation antisense oligonucleotides against β-catenin protect mice against diet-induced hepatic steatosis and hepatic and peripheral insulin resistance.
    Popov VB; Jornayvaz FR; Akgul EO; Kanda S; Jurczak MJ; Zhang D; Abudukadier A; Majumdar SK; Guigni B; Petersen KF; Manchem VP; Bhanot S; Shulman GI; Samuel VT
    FASEB J; 2016 Mar; 30(3):1207-17. PubMed ID: 26644352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CGI-58 knockdown sequesters diacylglycerols in lipid droplets/ER-preventing diacylglycerol-mediated hepatic insulin resistance.
    Cantley JL; Yoshimura T; Camporez JP; Zhang D; Jornayvaz FR; Kumashiro N; Guebre-Egziabher F; Jurczak MJ; Kahn M; Guigni BA; Serr J; Hankin J; Murphy RC; Cline GW; Bhanot S; Manchem VP; Brown JM; Samuel VT; Shulman GI
    Proc Natl Acad Sci U S A; 2013 Jan; 110(5):1869-74. PubMed ID: 23302688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of glycosylphosphatidylinositol-specific phospholipase D on hepatic diacylglycerol accumulation, steatosis, and insulin resistance in diet-induced obesity.
    Masuda S; Fujishima Y; Maeda N; Tsugawa-Shimizu Y; Nakamura Y; Tanaka Y; Obata Y; Fukuda S; Nagao H; Kita S; Nishizawa H; Shimomura I
    Am J Physiol Endocrinol Metab; 2019 Feb; 316(2):E239-E250. PubMed ID: 30457913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JTP-103237, a monoacylglycerol acyltransferase inhibitor, prevents fatty liver and suppresses both triglyceride synthesis and de novo lipogenesis.
    Okuma C; Ohta T; Tadaki H; Ishigure T; Sakata S; Taniuchi H; Sano R; Hamada H; Kume S; Nishiu J; Kakutani M
    J Pharmacol Sci; 2015 Jul; 128(3):150-7. PubMed ID: 26215699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting hepatic pyruvate dehydrogenase kinases restores insulin signaling and mitigates ChREBP-mediated lipogenesis in diet-induced obese mice.
    Wu CY; Tso SC; Chuang JL; Gui WJ; Lou M; Sharma G; Khemtong C; Qi X; Wynn RM; Chuang DT
    Mol Metab; 2018 Jun; 12():12-24. PubMed ID: 29656110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of C16:0 ceramide in the development of obesity and type 2 diabetes: CerS6 inhibition as a novel therapeutic approach.
    Raichur S; Brunner B; Bielohuby M; Hansen G; Pfenninger A; Wang B; Bruning JC; Larsen PJ; Tennagels N
    Mol Metab; 2019 Mar; 21():36-50. PubMed ID: 30655217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycerol-3-phosphate acyltransferase 1 deficiency in ob/ob mice diminishes hepatic steatosis but does not protect against insulin resistance or obesity.
    Wendel AA; Li LO; Li Y; Cline GW; Shulman GI; Coleman RA
    Diabetes; 2010 Jun; 59(6):1321-9. PubMed ID: 20200319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carboxylesterase 2a deletion provokes hepatic steatosis and insulin resistance in mice involving impaired diacylglycerol and lysophosphatidylcholine catabolism.
    Chalhoub G; Jamnik A; Pajed L; Kolleritsch S; Hois V; Bagaric A; Prem D; Tilp A; Kolb D; Wolinski H; Taschler U; Züllig T; Rechberger GN; Fuchs C; Trauner M; Schoiswohl G; Haemmerle G
    Mol Metab; 2023 Jun; 72():101725. PubMed ID: 37059417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a gene encoding MGAT1, a monoacylglycerol acyltransferase.
    Yen CL; Stone SJ; Cases S; Zhou P; Farese RV
    Proc Natl Acad Sci U S A; 2002 Jun; 99(13):8512-7. PubMed ID: 12077311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochanin A improves hepatic steatosis and insulin resistance by regulating the hepatic lipid and glucose metabolic pathways in diet-induced obese mice.
    Park HS; Hur HJ; Kim SH; Park SJ; Hong MJ; Sung MJ; Kwon DY; Kim MS
    Mol Nutr Food Res; 2016 Sep; 60(9):1944-55. PubMed ID: 27145114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ginsenosides reduce body weight and ameliorate hepatic steatosis in high fat diet‑induced obese mice via endoplasmic reticulum stress and p‑STAT3/STAT3 signaling.
    Yao Y
    Mol Med Rep; 2020 Mar; 21(3):1059-1070. PubMed ID: 32016448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Catalytic properties of MGAT3, a putative triacylgycerol synthase.
    Cao J; Cheng L; Shi Y
    J Lipid Res; 2007 Mar; 48(3):583-91. PubMed ID: 17170429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.